Financial results announcement

David Brennan, Chief Executive Officer, said:

Disciplined execution of our strategy has delivered a good performance in 2011 in the face of intensified pricing pressure and generic competition. Our strong cash flow supported a significant increase in cash distributions to shareholders and continued investment to drive future growth and value. While the further expected losses of market exclusivity make for a challenging 2012 outlook, we remain committed to a long-term, focused, R&D based strategy, and today we have announced further steps to drive productivity in all areas to improve returns on our investment in innovation.

Fourth quarter and full year results 2011

Announced on Thursday 2 February 2012

Downloads

Webcast

View the webcast

Teleconference replay

A recording of the analyst presentation and Q&A session will be available until 17:00 BST Wednesday 9 May, on the following numbers:

LocationNumberConference ID
UK (freephone) 0800 953 1533 67777263#
US (freephone) 1 866 247 4222 67777263#
International +44 (0)1452 55 00 00 67777263#

 

Management interviews

David Brennan

David Brennan, CEO updates on AstraZeneca’s results, strategy and outlook

Watch video

Martin Mackay

Martin Mackay, President R&D, discusses R&D performance and productivity

Watch video

Tony Zook

Tony Zook, EVP Commercial, talks about key brands and customer-facing initiatives

Watch video


Related information

In order to help analysts and investors estimate the impact of changing exchange rates on sales and earnings, the Company provides an annual 'currency sensitivity guide', alongside the rates upon which its earnings guidance is based.

2012 Currency Guidance